Featured Research

from universities, journals, and other organizations

How 'cleaving' protein drives tumor growth in prostate, other cancers

Date:
October 16, 2012
Source:
University of California - Los Angeles
Summary:
Researchers have determined how a protein known as Trop2 drives the growth of tumor cells in prostate and other epithelial cancers. This discovery is important because it may prove essential for creating new therapies that stop the growth of cancer, the researchers said.

Researchers led by Tanya Stoyanova and Dr. Owen Witte of UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have determined how a protein known as Trop2 drives the growth of tumor cells in prostate and other epithelial cancers.

This discovery is important because it may prove essential for creating new therapies that stop the growth of cancer, the researchers said. The study is featured on the cover of the Oct. 15 issue of the journal Genes and Development.

The Trop2 protein is expressed on the surface of many types of epithelial cancer cells -- cells that form tumors that grow in the skin and the inner and outer linings of organs -- but little was known about the protein's role in the growth and proliferation of cancer cells. The UCLA researchers discovered that Trop2 controls those processes through a mechanism that leads to the protein being cleaved into two parts, one inside the cell and one outside. This Trop2 division promotes self-renewal of the cancer cells, resulting in tumor growth.

"Determining the mechanism of this protein is important for planning treatments that stop the growth of prostate cancer, but it is also overexpressed in so many other types of cancer that it might be a treatment target for many more patients beyond that population," said senior author Witte, director of the Broad Center and a professor in the department of microbiology, immunology, and molecular genetics at UCLA.

The finding may have a critical clinical impact, the researchers said, since preventing the cleavage of Trop2 by mutating those sites on the protein where it splits eliminates the protein's ability to promote tumor cell growth. Using this knowledge, they said, new therapy strategies can be developed that block Trop2 molecular signaling, thus stopping its ability to enhance tumor growth in a variety of epithelial malignancies, including prostate, colon, oral cavity, pancreatic and ovarian cancers, among others.

"The reason I became interested in Trop2 was that it is highly expressed in many epithelial cancers but no one knew precisely how the protein worked to promote the disease," said Stoyanova, the study's first author and a postdoctoral scholar in the department of microbiology, immunology and molecular genetics at UCLA.

Funding for the study was provided by the California Institute for Regenerative Medicine Training Grant (TG2-01169), the U.S. Department of Defense Prostate Cancer Research Program (PC110638) and the Howard Hughes Medical Institute.


Story Source:

The above story is based on materials provided by University of California - Los Angeles. The original article was written by Shaun Mason. Note: Materials may be edited for content and length.


Journal Reference:

  1. T. Stoyanova, A. S. Goldstein, H. Cai, J. M. Drake, J. Huang, O. N. Witte. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via -catenin signaling. Genes & Development, 2012; 26 (20): 2271 DOI: 10.1101/gad.196451.112

Cite This Page:

University of California - Los Angeles. "How 'cleaving' protein drives tumor growth in prostate, other cancers." ScienceDaily. ScienceDaily, 16 October 2012. <www.sciencedaily.com/releases/2012/10/121016092845.htm>.
University of California - Los Angeles. (2012, October 16). How 'cleaving' protein drives tumor growth in prostate, other cancers. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/10/121016092845.htm
University of California - Los Angeles. "How 'cleaving' protein drives tumor growth in prostate, other cancers." ScienceDaily. www.sciencedaily.com/releases/2012/10/121016092845.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins